Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)
China · Delayed Price · Currency is CNY 53.64
+0.86 (1.63%)
At close: Oct 23, 2026
SHE:301075 Revenue
Tibet Duo Rui Pharmaceutical had revenue of 63.22M CNY in the quarter ending June 30, 2026, with 10.67% growth. This brings the company's total for the last twelve months to 143.26M, down -32.30% year-over-year. In the year 2025, Tibet Duo Rui Pharmaceutical had annual revenue of 154.18M, down -35.93%. That makes Tibet Duo Rui Pharmaceutical the 33,383rd largest company in the world by revenue and 5,077th in China.
Revenue (ttm)
143.26M
Revenue Growth
-32.30%
P/S Ratio
29.95
Revenue / Employee
310.76K
Employees
461
Market Cap
4.29B
Revenue by Segment
- Preparations 55.36M 35.9%
- Active Pharmaceutical Ingredient (api) 49.74M 32.3%
- Intermediate 38.96M 25.3%
- Others 10.11M 6.6%
Fiscal year ended Dec 31, 2025 See the full SHE:301075 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.18M | -86.45M | -35.93% |
| Dec 31, 2024 | 240.63M | -93.67M | -28.02% |
| Dec 31, 2023 | 334.30M | -66.75M | -16.64% |
| Jan 1, 2023 | 401.05M | -128.57M | -24.28% |
| Jan 1, 2022 | 529.62M | 39.45M | 8.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.12B |
| Hunan Fangsheng Pharmaceutical | 1.87B |
| Fuan Pharmaceutical (Group) | 1.66B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.56B |
| Tianjin Lisheng Pharmaceutical | 1.30B |
| LanZhou Foci Pharmaceutical | 926.49M |
| Teyi Pharmaceutical Group Co.,Ltd | 826.71M |
| Zhongzhu Healthcare Holding Co.,Ltd | 533.88M |